Publications 2022

Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frolund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N (2022)
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Eur. J. Haematol., 108 (1), 34-44
DOI 10.1111/ejh.13709

Publications 2021

Kaiser M, Beksac M, Gulbrandsen N, Schjesvold F, Hajek R, Moreau P, de la Fuente FD, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng ZY, Labotka R, Dimopoulos MA (2021)
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (vol 99, pg 1793, 2020)
Ann. Hematol., 100 (1), 297-302
DOI 10.1007/s00277-020-04302-0

Tjonnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
Monoclonal gammopathy of clinical importance
Tidsskr. Nor. Laegeforen., 141 (13), 1276-1280

Publications 2020

Kaiser M, Beksac M, Gulbrandsen N, Schjesvold F, Hajek R, Moreau P, de la Fuente FD, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng ZY, Labotka R, Dimopoulos MA (2020)
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Ann. Hematol., 99 (8), 1793-1804
DOI 10.1007/s00277-020-04149-5

Publications 2018

Tangen JM, Tjonnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, Oslo Myeloma Ctr (2018)
Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
BMC Cancer, 18, 801
DOI 10.1186/s12885-018-4722-x

Publications 2012

Hjorth M, Hjertner O, Knudsen LM, Gulbrandsen N, Holmberg E, Pedersen PT, Andersen NF, Andreasson B, Billstrom R, Carlson K, Carlsson MS, Flogegard M, Forsberg K, Gimsing P, Karlsson T, Linder O, Nahi H, Othzen A, Swedin A, NMSG (2012)
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Eur. J. Haematol., 88 (6), 485-496
DOI 10.1111/j.1600-0609.2012.01775.x

Publications 2011

Nilsson-Ehle H, Birgegard G, Samuelsson J, Antunovic P, Astermark J, Garelius H, Engstrom LM, Kjeldsen L, Nilsson L, Olsson A, Skov-Holm M, Wallvik J, Gulbrandsen N, Hellstrom-Lindberg E (2011)
Quality of life, physical function and MRI T2*in elderly low-risk MDS patients treated to a haemoglobin level of >= 120 g/L with darbepoetin alfa +/- filgrastim or erythrocyte transfusions
Eur. J. Haematol., 87 (3), 244-252
DOI 10.1111/j.1600-0609.2011.01654.x

Publications 2010

Iversen PO, Wisloff F, Gulbrandsen N (2010)
Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support
Clin. Nutr., 29 (4), 488-491
DOI 10.1016/j.clnu.2009.12.002

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukas E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, Sorbo JH, Wisloff F, Juliusson G, Turesson I et al. (2010)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Blood, 116 (9), 1405-1412
DOI 10.1182/blood-2009-08-237974

Publications 2009

Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, D'Sa S, Soutar R, Waage A, Gulbrandsen N, Gregersen H, Low E, Haematooncology Task Force British UK Myeloma Forum Nordic Myeloma St (2009)
UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)
Br. J. Haematol., 147 (1), 22-42
DOI 10.1111/j.1365-2141.2009.07807.x

Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009)
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
Eur. J. Haematol., 83 (4), 279-289
DOI 10.1111/j.1600-0609.2009.01303.x

Publications 2008

Iversen PO, Ukrainchenko E, Afanasyev B, Hulbekkmo K, Choukah A, Gulbrandsen N, Wisloff F, Tangen JM (2008)
Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia
Leuk. Lymphoma, 49 (10), 1916-1924
DOI 10.1080/10428190802339723

Piehler AP, Gulbrandsen N, Kierulf P, Urdal P (2008)
Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population
Clin. Chem., 54 (11), 1823-1830
DOI 10.1373/clinchem.2008.106153

Publications 2006

Gulbrandsen N (2006)
Health related quality of life and cost-utility in the treatment of multiple myeloma
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 437, 1 b. (flere pag.)
BIBSYS 061837156